Literature DB >> 34475361

Rectal Chlamydia trachomatis Infection: A Narrative Review of the State of the Science and Research Priorities.

Christine M Khosropour1, Julia C Dombrowski, Lucia Vojtech2, Dorothy L Patton2, Lee Ann Campbell3, Lindley A Barbee, Michaela C Franzi4, Kevin Hybiske.   

Abstract

ABSTRACT: Chlamydia trachomatis (CT) is the most commonly reported infection in the United States. Most chlamydial research to date has focused on urogenital infection, but a growing body of research has demonstrated that rectal chlamydia is a relatively common infection among clinic-attending men and women. We know that most rectal CT infections are asymptomatic, but the health implications of these infections, particularly for women, are unclear. In addition, there are key knowledge gaps related to the epidemiologic parameters of rectal chlamydia, the routes of acquisition, the duration of infection, and the clinical significance of a positive rectal CT test result. This lack of information has led to a blind spot in the potential role of rectal chlamydia in sustaining high levels of CT transmission in the United States. Furthermore, recent findings from animal models suggest that the immune response generated from gastrointestinal chlamydial infection can protect against urogenital infection; however, it remains to be determined whether rectal chlamydia similarly modulates anti-CT immunity in humans. This is a critical question in the context of ongoing efforts to develop a CT vaccine. In this narrative review, we summarize the state of the science for rectal chlamydia and discuss the key outstanding questions and research priorities in this neglected area of sexual health research.
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34475361      PMCID: PMC8595876          DOI: 10.1097/OLQ.0000000000001549

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  27 in total

1.  Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis.

Authors:  Nastassya L Chandra; Claire Broad; Kate Folkard; Katy Town; Emma M Harding-Esch; Sarah C Woodhall; John M Saunders; S Tariq Sadiq; J Kevin Dunbar
Journal:  Sex Transm Infect       Date:  2018-02-03       Impact factor: 3.519

2.  A Population-Based Study to Compare Treatment Outcomes Among Women With Urogenital Chlamydial Infection in Washington State, 1992 to 2015.

Authors:  Christine M Khosropour; Teal R Bell; James P Hughes; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2018-05       Impact factor: 2.830

3.  Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003.

Authors:  Charlotte K Kent; Janice K Chaw; William Wong; Sally Liska; Steven Gibson; Gregory Hubbard; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2005-05-26       Impact factor: 9.079

4.  Estimates of the Prevalence and Incidence of Chlamydia and Gonorrhea Among US Men and Women, 2018.

Authors:  Kristen M Kreisel; Emily J Weston; Sancta B St Cyr; Ian H Spicknall
Journal:  Sex Transm Dis       Date:  2021-04-01       Impact factor: 2.830

5.  New Human Immunodeficiency Virus Diagnosis Independently Associated With Rectal Gonorrhea and Chlamydia in Men Who Have Sex With Men.

Authors:  Lindley A Barbee; Christine M Khosropour; Julia C Dombrowksi; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2017-07       Impact factor: 2.830

6.  Factors associated with anorectal Chlamydia trachomatis or Neisseria gonorrhoeae test positivity in women: a systematic review and meta-analysis.

Authors:  Andrew Lau; Fabian Yuh Shiong Kong; Willa Huston; Eric P F Chow; Christopher K Fairley; Jane S Hocking
Journal:  Sex Transm Infect       Date:  2019-05-16       Impact factor: 3.519

7.  Sexually Transmitted Infections Treatment Guidelines, 2021.

Authors:  Kimberly A Workowski; Laura H Bachmann; Philip A Chan; Christine M Johnston; Christina A Muzny; Ina Park; Hilary Reno; Jonathan M Zenilman; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2021-07-23

8.  Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial.

Authors:  Julia C Dombrowski; Michael R Wierzbicki; Lori M Newman; Jonathan A Powell; Ashley Miller; Dwyn Dithmer; Olusegun O Soge; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2021-09-07       Impact factor: 9.079

9.  Is it time to switch to doxycycline from azithromycin for treating genital chlamydial infections in women? Modelling the impact of autoinoculation from the gastrointestinal tract to the genital tract.

Authors:  Andrew P Craig; Fabian Y S Kong; Laxmi Yeruva; Jane S Hocking; Roger G Rank; David P Wilson; Basil Donovan
Journal:  BMC Infect Dis       Date:  2015-04-30       Impact factor: 3.090

10.  Lymphogranuloma venereum is on the rise in Belgium among HIV negative men who have sex with men: surveillance data from 2011 until the end of June 2017.

Authors:  Irith De Baetselier; Achilleas Tsoumanis; Ruth Verbrugge; Bénédicte De Deken; Hilde Smet; Saïd Abdellati; Vicky Cuylaerts; Ludwig Apers; Tania Crucitti
Journal:  BMC Infect Dis       Date:  2018-12-20       Impact factor: 3.090

View more
  2 in total

1.  Nanoparticle-Based Lateral Flow Biosensor Integrated With Loop-Mediated Isothermal Amplification for Rapid and Visual Identification of Chlamydia trachomatis for Point-of-Care Use.

Authors:  Xu Chen; Qingxue Zhou; Yan Tan; Ronghua Wang; Xueli Wu; Jiangli Liu; Rui Liu; Shuoshi Wang; Shilei Dong
Journal:  Front Microbiol       Date:  2022-07-12       Impact factor: 6.064

2.  Anatomic Site-Specific Gonorrhea and Chlamydia Testing and Incidence Among People With HIV Engaged in Care at 4 US Clinical Centers, 2014-2018.

Authors:  Timothy W Menza; Stephen A Berry; Julie Dombrowski; Edward Cachay; Heidi M Crane; Mari M Kitahata; Kenneth H Mayer
Journal:  Open Forum Infect Dis       Date:  2022-06-17       Impact factor: 4.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.